Brister Mark 4
4 · OBALON THERAPEUTICS INC · Filed Nov 2, 2017
Insider Transaction Report
Form 4
Brister Mark
VP of Research and Development
Transactions
- Award
Common Stock
2017-10-31$7.17/sh+1,860$13,336→ 163,870 total
Footnotes (1)
- [F1]These shares were acquired under the Obalon Therapeutics, Inc. 2016 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).